We evaluated short-term prognoses and identified independent risk factors for both groups, clarifying that the combination of PD-1 inhibitors and VEGF inhibitors can improve the tumor immune tolerance microenvironment of MSS/pMMR advanced colon cancer, enhance the effectiveness of immune therapy, provide more clinical evidence for subsequent large-sample clinical studies, and establish a theoretical basis for personalized immunotherapy of MSS/pMMR colon cancer. Here, VEGFA is linked to colonic neoplasm.